Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Rhea-AI Summary

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has initiated patient recruitment for its Phase 2a clinical trial aimed at treating skin disorders linked to epidermal growth factor receptor (EGFR) inhibitor therapy. The company has selected three clinical sites in St. Louis, Miami, and Houston for the trial, which will also include a follow-up Phase 2b safety and efficacy study. The EGFR inhibitors are essential for treating several cancers, including non-small cell lung cancer and breast cancer. CEO Robb Knie emphasized that this selection marks a significant milestone for Hoth as they prepare to begin enrollment.

Positive

• Initiation of patient recruitment for Phase 2a clinical trial.
• Selection of reputable clinical sites in major U.S. cities.
• Potential to address skin disorders associated with EGFR inhibitors, critical for several cancer treatments.

Negative

• None.

Patient Recruitment Underway

NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical  company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer. The phase 2a dose ranging study as well as a proposed follow-up phase 2b safety and efficacy dose extension study; both studies will be conducted in cancer patients receiving EGFR inhibitor therapy.).

The initial 3 clinical sites for the Phase 2a  are located across the United States in the following cities:
St Louis, MO
Miami, FL
Houston, TX

"We are pleased to have selected our initial clinical sites," said Robb Knie, the Company's CEO. "The caliber of the clinics selected represents some of the best cancer treatment facilities in the country. This selection process represents a major milestone for Hoth and we look forward to initiating patient enrollment."

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options.  To learn more, please visit https://ir.hoththerapeutics.com/.

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions including, but not limited to, market and other conditions. These statements concern the intended use of net proceeds from the private placement, Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com 
www.hoththerapeutics.com 
Phone: (678) 570-6791

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-selection-of-first-3-clinical-sites-for-its-phase-2-clinical-trial-to-treat-cancer-disorders-associated-with-epidermal-growth-factor-receptor-egfr-inhibitor-therapy-301730165.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What is the purpose of Hoth Therapeutics' Phase 2a clinical trial?

The Phase 2a clinical trial aims to treat rash and skin disorders associated with EGFR inhibitor therapy in cancer patients.

When was the patient recruitment announcement made by Hoth Therapeutics?

Patient recruitment was announced on January 25, 2023.

Where are the clinical trial sites located?

The initial clinical sites are located in St. Louis, MO, Miami, FL, and Houston, TX.

What is the significance of EGFR inhibitors in cancer treatment?

EGFR inhibitors are crucial for the treatment of various cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer.

What are the next steps for Hoth Therapeutics following this announcement?

The next step is to initiate patient enrollment at the selected clinical sites for the trial.